Further, the treatment of cisplatin resistant ovarian cancer cells (cis-A2780) with the MEK1/2 inhibitor cobimetinib sensitized the human ovarian cancer cell lines to cisplatin-induced cell death. This evidence concerns the gene MAP2K1 and ovarian cancer.